CJC-1295 with DAC overview:
------
Description:
-
CJC-1295 with DAC (Drug Affinity Complex) is a synthetic analog of growth hormone-releasing hormone (GHRH) designed to increase the production and secretion of endogenous growth hormone (GH) and insulin-like growth factor 1 (IGF-1). It is a modified form of GHRH that includes the addition of a Drug Affinity Complex (DAC) to extend its half-life and enhance its bioavailability. CJC-1295 with DAC is used in research settings to investigate the effects of sustained GH release on metabolic processes, muscle growth, and recovery.
-----
Mechanism of Action:
-
CJC-1295 with DAC functions by binding to and activating the growth hormone-releasing hormone receptor (GHRHr) located in the pituitary gland. The mechanism can be broken down as follows:
-
1. Receptor Activation:
CJC-1295 mimics natural GHRH, binding to the GHRH receptor on the somatotroph cells of the anterior pituitary.
-
This binding stimulates the production and release of growth hormone in a pulsatile manner, similar to endogenous GH release patterns.
------
2. Extended Half-Life via DAC:
The DAC component allows CJC-1295 to bind to albumin in the bloodstream, which significantly prolongs its half-life.
-
Without DAC, the half-life of GHRH analogs is typically measured in minutes, whereas CJC-1295 with DAC has a half-life of approximately 6 to 8 days.
-
This extended activity reduces the frequency of dosing required to maintain elevated GH levels.
------
3. Downstream Effects:
Increased GH levels stimulate the liver to produce higher levels of insulin-like growth factor 1 (IGF-1).
-
Elevated IGF-1 enhances protein synthesis, muscle growth, and tissue repair.
-
GH and IGF-1 also increase lipolysis (fat breakdown) and improve overall metabolic function.
-----
Molecular Structure and Sequence:
-
Molecular Formula: C165H269N47O46
-
Molecular Weight: Approximately 3647.29 Daltons (Da)
-
Amino Acid Sequence:
Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-Gly-Gly-Gly-Cys-Ala-Trp-Ser-Val-Gly-Arg-Leu-NH2
-
The amino acid sequence is modified to enhance binding affinity and resistance to enzymatic degradation, contributing to its prolonged activity when combined with DAC.
-----
Pharmacokinetics:
-
Administration: Typically administered via subcutaneous injection in research settings.
-
Half-life: 6–8 days due to the DAC modification.
-
Bioavailability: High due to resistance to enzymatic degradation and albumin binding.
-----
Research Applications:
-
CJC-1295 with DAC is primarily studied for its potential effects on:
-
Increasing lean muscle mass and strength.
-
Enhancing fat loss through increased lipolysis.
-
Improving recovery from injury and exercise.
-
Modulating sleep patterns and overall health via increased GH and IGF-1 levels.
-----
**CJC-1295 with DAC is intended for research purposes only and is not approved for human consumption. It is not intended to diagnose, treat, cure, or prevent any disease. All research should be conducted by qualified professionals in a controlled laboratory setting. Misuse or unauthorized use may result in adverse health effects.